Nanox Imaging Ltd. (NASDAQ: NNOX) has taken a significant step in expanding the reach of its AI-driven diagnostic tools by signing an exclusive reseller agreement for its HealthOST bone analysis solution in the United Kingdom. The agreement, announced through its subsidiary Nanox AI Ltd., grants Vertec Scientific Ltd. the exclusive rights to market and resell HealthOST in the UK for an initial three-year term, subject to minimum annual license commitments. This move underscores the growing adoption of AI in medical imaging and the strategic importance of the UK market for Nanox.
HealthOST is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes routine CT scans to assist clinicians in evaluating musculoskeletal diseases of the spine, including osteoporosis. The solution is designed to opportunistically detect vertebral fragility fractures, a common yet often underdiagnosed condition, especially in older adults. The clinical significance of such early detection cannot be overstated, as it can lead to timely interventions and improved patient outcomes, potentially reducing the burden on healthcare systems.
The agreement comes on the heels of a pivotal development in November 2025, when the National Institute for Health and Care Excellence (NICE) recommended HealthOST and its predecessor, HealthVCF, among five AI technologies for use in the National Health Service (NHS). This recommendation positions the AI solutions as viable options for opportunistic screening of vertebral fragility fractures, a move that could transform standard radiological practice. By integrating AI into routine CT scan interpretations, clinicians can identify at-risk patients who might otherwise go undiagnosed, thereby enabling earlier treatment and management of osteoporosis and related conditions.
The UK market presents a substantial opportunity for Nanox, given the NHS's commitment to integrating innovative technologies that enhance diagnostic accuracy and efficiency. The exclusive partnership with Vertec Scientific, a company with established distribution channels in the UK healthcare sector, is expected to accelerate the adoption of HealthOST across NHS trusts and private healthcare providers. Vertec's expertise in medical equipment distribution will likely facilitate smoother integration into clinical workflows, addressing the practical challenges of deploying AI solutions in real-world settings.
For Nanox, this agreement is part of a broader strategy to commercialize its AI portfolio and expand its global footprint. The company's vision is to drive the transition to preventive healthcare by providing an integrated platform that includes affordable imaging hardware, AI-based solutions, and cloud-based services. HealthOST's success in the UK could serve as a catalyst for similar partnerships in other regions, particularly in Europe and Asia, where healthcare systems are increasingly looking to leverage AI to improve diagnostic capabilities and manage rising healthcare costs.
The implications of this announcement extend beyond commercial gains. The NICE recommendation and subsequent adoption of AI tools like HealthOST highlight a paradigm shift in how chronic diseases such as osteoporosis are detected and managed. Traditional diagnostic methods often rely on dual-energy X-ray absorptiometry (DXA) scans, which are underutilized and not always accessible. AI-powered analysis of routine CT scans offers a more opportunistic and widespread screening approach, potentially reaching a larger patient population without additional scanning or radiation exposure.
Moreover, the integration of AI in radiology has the potential to alleviate the workload of radiologists, who are often overburdened with increasing imaging volumes. By flagging suspicious findings, AI can help prioritize cases and reduce the risk of oversight, thereby improving diagnostic accuracy and efficiency. This not only benefits patients but also enhances the sustainability of healthcare systems facing workforce shortages.
In conclusion, Nanox's exclusive reseller agreement with Vertec Scientific marks a significant milestone in the commercialization of its AI bone solution in the UK. With NICE's endorsement and the support of a seasoned distributor, HealthOST is well-positioned to make a meaningful impact on the early detection of osteoporosis and vertebral fractures. As AI continues to reshape the medical imaging landscape, Nanox is at the forefront of this transformation, offering solutions that align with the global push toward preventive and precision medicine. The success of this partnership could pave the way for broader adoption of AI-driven diagnostics, ultimately improving patient care and health outcomes across the UK and beyond.
